SITC 2022 | Results of a Phase II trial of vidutolimod and nivolumab in melanoma

Diwakar Davar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses results from a Phase II study (NCT04401995) of vidutolimod, a CpG-A toll-like receptor 9 (TLR9) inhibitor, with nivolumab in patients with high-risk resectable melanoma. Approximately half of patients receiving vidutolimod and nivolumab reported a pathological complete response (pCR), comparable to more recent treatments including relatlimab and PD-L1 inhibitors. Almost all patients were additionally disease free 2 years post-treatment and Dr Davar also talks on mechanisms of resistance observed. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.